Blog

AcuraStem Enters into a License Agreement with Takeda to Advance PIKFYVE Therapeutics
Sep 25, 2023, 9:30 AM
Agreement enables the development of therapeutics, including AcuraStem’s AS-202 Candidate, an antisense oligonucleotide that suppresses levels of the PIKFYVE kinase
Topics
Archives